Talk:Tivantinib

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

A summary of this article appears in C-Met_inhibitors.

Need results of the phase 3 trial

or at least some idea of when likely. - Rod57 (talk) 02:42, 13 November 2015 (UTC)[reply]

Done - METIV-HCC failed. - Rod57 (talk) 19:03, 20 February 2017 (UTC)[reply]

Propose removal of template Intracellular chemotherapeutic agents

It seems pointless to transclude the template:Intracellular chemotherapeutic agents since it does not and should not include tivantinib. - Could replace with see also ? - Rod57 (talk) 19:02, 20 February 2017 (UTC)[reply]

Proposed change re template Growth factor receptor modulators

Template Growth factor receptor modulators does mention tivantinib (amongst many others). Sadly that makes it impossible to see what links (directly) to tivantinib. If we change the transclude to a see also at least tivantinib wont appear to link to all the others. - Will try it. - Rod57 (talk) 19:14, 20 February 2017 (UTC)[reply]

ArQule was a fraud

I made the mistake of quitting a perfectly good job in Canada working for one of the worlds biggest generic pharmaceutical manufacturers to work at ArQule for only 36K and no relocation. ArQule claimed to be at the cutting edge of "automating" chemistry but it was all a lie, their VP of chemistry, David Coffen, was so computer illiterate he didn't even have one on his desk, his secretary had to print his emails, no one would do business with ArQule and I later found out they were literally weeks from bankruptcy, bouncing people's paychecks. I was one of the only people that had a job before ArQule, the rest of them were all unemployed prior.

It was I who convinced Solvay Duphar that they might know something about how to apply automation to chemistry, they themselves said in bewilderment that I seemed to be the only person who knew anything about it. The reason was my knowledge of electronics from my Father, a PhD electrical engineer and mentor to the guy who founded the Deshpande Center at MIT. I also had 7 years of mechanical and machining skills prior to even beginning my studies in chemistry. The rest of them were all making close to 100K and knew nothing except what they learned in grad school, they paid me 36. ArQule never automated chemistry, they had a team of people with high school diplomas working on the "production floor" doing things by hand with a little help from fluid handlers build for biology. I was the only person really working on automating chemistry as evidenced by my 98 Boston ACS meeting presentation on how to handle pyrophoric reagents with fluid handlers. I also solved many chemistry problems that people beyond my degree level floundered on such as making crystalline oxazalones necessary for library production.

The chemists at ArQule were so incensed that I was operating at their level and beyond they continually complained to management and harassed me, I was assaulted and threatened by people at ArQule. When my girlfriend and I, along with 20 other families lost everything we had when an arsonist set fire to our building in Melrose, MA, ArQule people actually cracked jokes to my face about it. Despite making these people rich, saving them from bankruptcy etc. they still felt the need to slander and defame me, trying to prevent me from earning a livelihood as a chemist ever since.

I later contacted Seth Harrison to remind him of what I had done for him and what his people were doing to me but he had no response, he sure didn't mind me quitting my job to come and save his operation though.

The VP and his sidekick (who's professor told him he should do something else with his life) actually threatened me with my job if I didn't say I had done certain chemistry with robotics that I had painstakingly done by hand. The VP of chemistry was adamant that automation of chemistry was nonsense and they would just do things by hand despite the fact they were telling investors otherwise. They lied to investors and paid themselves all exorbitant salaries when no one else wanted to give them a job otherwise.

In the end no medicine has ever come from ArQule, if anything these acquisitions from big pharma are only to try and eliminate competition, keeping the cost of prescription medications high.

Please look for and read an article by doctors without borders titled "6 things big pharma doesn't want you to know"

https://www.doctorswithoutborders.org/latest/six-things-big-pharma-doesnt-want-you-know Steve Brackett (talk) 08:49, 29 July 2023 (UTC)[reply]